Feb 02,2023

Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2022. In Q4 2022, worldwide revenue was $7.30 billion, a decrease of 9% compared with Q4 2021, driven by a 4% decrease from the unfavorable impact of foreign exchange rates, a 3% decrease due to lower realized prices, and a 2% decrease in volume. For Q4 2022, worldwide Mounjaro revenue was $279.2 million. U.S. revenue was $256.7 million. Mounjaro launched in the U.S. for the treatment of type 2 diabetes in June 2022.

View Analyst & Ambassador Comments
Go to original news
Feb 02,2023

Global Continuous Subcutaneous Insulin Infusion Market 2022 - 2027: Featuring Byram Healthcare Centers, Cellenovo, CeQur SA and SOOIL Development Among Others

The Global Continuous Subcutaneous Insulin Infusion Market is estimated to be USD 2.41 Bn in 2022 and is expected to reach USD 4.25 Bn by 2027, growing at a CAGR of 12.02%

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 06,2023

Glooko picks up security certification for diabetes patient management platform

Glooko announced today that it received ISO 27001 certification for its data management and remote patient monitoring platforms. Compliance confirms that Glooko offers a comprehensive security management program and follows gold-standard practices, according to a news release.

PRODUCT

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 06,2023

DarioHealth Announces Preliminary Fourth Quarter and Full Year 2022 Operating Results

DarioHealth Corp. today announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively. Preliminary Results demonstrate success in B2C to B2B transformation. B2B expected to represent approximately 60% of revenue in 2022 versus 4% in 2021.

View Analyst & Ambassador Comments
Go to original news
Feb 06,2023

Smart Insulin Pens Market Size to Reach USD 302.1 Million in 2030

The smart insulin pens market size reached USD 107.2 Million in 2021 and is expected to register a CAGR of 12.1% during the forecast period. A major factor driving revenue growth of smart insulin pens market is increasing prevalence of diabetes.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Oct 27,2022

Ypsomed leaves DiaExpert in new hands and focuses on own products

Ypsomed and Mediq have signed an agreement on the sale of DiaExpert. DiaExpert is an established specialist and mail-order retailer for the care of people with diabetes in Germany, specialised in insulin pump therapy. With the sale, DiaExpert will remain as a helping hand for customers and health insurers and will continue its services. Ypsomed is focusing more strongly on the development, manufacture and sale of its own high-quality medical technology products for people with chronic conditions.

COLLABORATION MERGERS & ACQUISITION

#product & service

View Analyst & Ambassador Comments
Go to original news
Nov 16,2022

Ypsomed doubles profits and confirms outlook

Ypsomed is on track and achieved consolidated sales of CHF 244.2 million in the first half of the 2022/23 financial year (previous year: CHF 222.6 million). This corresponds to a growth of 9.7% compared with the previous year. At constant currency rates compared to the previous year, this would have represented an increase of around 13%.

View Analyst & Ambassador Comments
Go to original news
Dec 01,2022

Global Diabetes Insulin Delivery Pen Market 2022-2028: Focus on United States, UK, Canada France, Italy, Spain, Germany, Netherlands, Poland, Sweden, Turkey, Australia, Japan, China, India, & Brazil

Taking into consideration the COVID-19 crisis, the global diabetes insulin delivery pen market is expected to grow from an estimated value of USD 16,975 million in 2022 to USD 22,170 million by 2028.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Dec 01,2022

Dexcom G6 CGMs win reimbursement coverage in Japan

Terumo announced today that the Japanese medical insurance system expanded reimbursement coverage for the Dexcom G6 CGM. Japan’s medical insurance system introduced a new category titled “C150.” It makes a wider range of people with diabetes eligible to receive reimbursement for the G6 continuous glucose monitor (CGM) in Japan. Terumo markets the G6 in Japan, according to a news release.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 01,2022

Two New Employers Join Dario Through Benefits Brokerage Partner

DarioHealth Corp. announced today that two employers selected Dario as part of an offering from a leading benefits brokerage partner that Dario had previously announced. The employers will deploy Dario's solutions to help improve the cardiometabolic and musculoskeletal health of employees beginning in the first quarter of 2023.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES